Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

Jaishri O BlakeleyStuart A GrossmanAndrew S ChiTom MikkelsenMyrna R RosenfeldManmeet S AhluwaliaLouis Burt NaborsApril EichlerIgnacio Garcia RibasSerena DesideriXiaobu Yenull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Iniparib is well tolerated with radiotherapy and temozolomide in patients with newly diagnosed GBM at up to 17.2 mg/kg weekly. The primary objective of improved mOS compared with a historical control was met, indicating potential antitumor activity of iniparib in this setting. Dosing optimization (frequency and sequence) is needed prior to additional efficacy studies.

Keyphrases

newly diagnosed
locally advanced
phase ii study
rectal cancer
squamous cell carcinoma
radiation therapy
quantum dots
tyrosine kinase
room temperature
early stage
open label
human health
gold nanoparticles
amino acid
transition metal